In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria

The antibacterial activity of BAY y 3118, a new chlorofluoroquinolone, was determined against 257 strains of anaerobic bacteria and compared with the activities of ofloxacin, ciprofloxacin, sparfloxacin, imipenem, cefoxitin, clindamycin, chloramphenicol, metronidazole, and ornidazole. Overall, BAY y 3118 was the most active agent tested against the Bacteroides fragilis group. Its activity (MIC90, 0.5 mg/L) was 16-fold lower than that of sparfloxacin (MIC90, 8 mg/L), and more than 100-fold lower than that of ofloxacin (MIC90, 64 mg/L) and ciprofloxacin (MIC90, 128 mg/L) against the group. No strains belonging to this group were resistant to metronidazole (MICs range, 0.12-2 mg/L) and ornidazole (MICs range, 0.12-4 mg/L). BAY y 3118 was more active than those quinolones against Prevotella and Porphyromonas spp., Fusobacterium spp., Clostridium perfringens and C. difficile (MIC90, 0.12, 0.06, 0.12 and 0.25 mg/L, respectively). The activity of BAY y 3118 against Peptostreptococcus spp. (MIC90, 1 mg/L) was slightly lower than that of the other Gram-positive bacteria tested. In general, BAY y 3118 was more active than cefoxitin, and it was superior to antianaerobic chemical agents like metronidazole, ornidazole and clindamycin. Pharmacokinetic and clinical trials are required to define the role of BAY y 3118 in the treatment of anaerobic infections.